Moderna claims that its COVID-19 vaccine is 94.5% effective
Moderna claims that its COVID-19 vaccine is 94.5% effective. Beyond Pfizer! Moderna claims that its COVID-19 vaccine is 94.5% effective. On November 16, US biotechnology company Moderna announced that its new coronavirus vaccine mRNA-1273 has an effective rate of 94.5% and plans to apply to the United States for emergency use of the new coronavirus vaccine in the next few weeks.
Prior to November 11, Moderna had released news that the case accurual of the first interim analysis of the COVID-19 vaccine phase III clinical study has been completed.
Moderna said the company hopes that the first interim analysis will include more than 53 cases, which will help determine the efficacy of the vaccine. The data of these cases are being prepared to be submitted to the independent Data Security Monitoring Board (DSMB) for analysis and recommendations. Moderna does not know whether the participants will receive the vaccine or placebo.
On July 27 2020, Moderna issued a statement saying that the COVID-19 vaccine developed has entered the third phase of research and began to administer to participants.
In the latest statement, Moderna introduced that the third phase of the COVID-19 vaccine study included more than 7,000 Americans over 65 years old, and more than 5,000 Americans under 65 years old, who are at high risk. Of chronic diseases, such as diabetes, severe obesity and heart disease, which increase their risk of severe COVID-19.
Public information shows that Moderna was incorporated in 2010 and officially started operations in 2011. In 2018, Moderna was listed on NASDAQ(11879.1657, 49.88, 0.42%) . Moderna is committed to building an industry-leading mRNA technology platform to accelerate the development of new drugs.
In terms of the COVID-19 vaccine, the company has developed an mRNA vaccine called mRNA-1273. The vaccine was announced on February 24 and was shipped to the National Institute of Allergy and Infectious Diseases (NIAID) to start the first phase. the study.
On July 28, Moderna announced that the results of a preclinical study evaluating the mRNA-1273 COVID-19 vaccine were published in the New England Journal of Medicine. The study showed that in the upper and lower respiratory tracts of non-human primates, a two-dose vaccination regimen of mRNA-1273 can produce a powerful immune response and protection against new coronavirus infections.
It is worth noting that Moderna’s COVID-19 vaccine is both an mRNA vaccine and Pfizer vaccine, which has previously claimed an effective rate of more than 90%.
Stimulated by the above-mentioned news, Moderna rose more than 8% before the market.